Raphael Pharmaceutical Inc. carries a market capitalization of 28.25M, placing it among publicly traded companies globally.
| Market Cap | 28.25M |
| Enterprise Value | N/A |
Raphael Pharmaceutical Inc. currently has 20.18M shares outstanding.
| Shares Outstanding | 20.18M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -2.72 |
| P/TBV Ratio | -16.69 |
| P/FCF Ratio | -616.30 |
| P/OCF Ratio | -616.30 |
Raphael Pharmaceutical Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -80.23 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -2,247.92 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Raphael Pharmaceutical Inc.'s stock has gained approximately 315.43027% over the past 52 weeks. The 50-day moving average sits at 1.40, while the 200-day moving average is 1.10.
| Beta (5Y) | N/A |
| 52-Week Price Change | 315.43027% |
| 50-Day Moving Average | 1.40 |
| 200-Day Moving Average | 1.10 |
| Average Volume (20 Days) | N/A |
EBITDA reached -1.04M, while operating income came in at -1.04M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -1.04M |
| Pretax Income | -1.08M |
| Net Income | -1.08M |
| EBITDA | -1.04M |
| EBIT | -1.04M |
| Earnings Per Share (EPS) | -0.05 |
Total book value stands at -10.19M, with working capital of -1.66M providing operational flexibility.
| Cash & Cash Equivalents | 1,000.00 |
| Total Debt | N/A |
| Net Debt | 36,000.00 |
| Equity (Book Value) | -10.19M |
| Book Value Per Share | -0.51 |
| Working Capital | -1.66M |
Raphael Pharmaceutical Inc. produced -45,000.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -45,000.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -45,000.00 |
| FCF Per Share | 0.00 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.01 |
| FCF Yield | -0.16 |
Raphael Pharmaceutical Inc. posts an Altman Z-Score of -6,654.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6,654.84 |